Par-4 Links Dopamine Signaling and Depression  by Park, Sang Ki et al.
Cell, Vol. 122, 275–287, July 29, 2005, Copyright ©2005 by Elsevier Inc. DOI 10.1016/j.cell.2005.05.031
Par-4 Links Dopamine Signaling and DepressionSang Ki Park,1 Minh Dang Nguyen,1,3
André Fischer,1,3 Margaret Po-Shan Luke,1
El Bachir Affar,1 Paul Brian Dieffenbach,2
Huang-Chun Tseng,1 Yang Shi,1 and Li-Huei Tsai1,*
1Department of Pathology
Howard Hughes Medical Institute
Harvard Medical School
77 Avenue Louis Pasteur
Boston, Massachusetts 02115
2Harvard-MIT Division of Health Sciences
and Technology
77 Massachusetts Avenue, E25–519
Cambridge, Massachusetts 02139
Summary
Prostate apoptosis response 4 (Par-4) is a leucine zip-
per containing protein that plays a role in apoptosis.
Although Par-4 is expressed in neurons, its physio-
logical role in the nervous system is unknown. Here
we identify Par-4 as a regulatory component in dopa-
mine signaling. Par-4 directly interacts with the dopa-
mine D2 receptor (D2DR) via the calmodulin binding
motif in the third cytoplasmic loop. Calmodulin can
effectively compete with Par-4 binding in a Ca2+-
dependent manner, providing a route for Ca2+-medi-
ated downregulation of D2DR efficacy. To examine the
importance of the Par-4/D2DR interaction in dopa-
mine signaling in vivo, we used a mutant mouse lack-
ing the D2DR interaction domain of Par-4, Par-4DLZ.
Primary neurons from Par-4DLZ embryos exhibit an
enhanced dopamine-cAMP-CREB signaling pathway,
indicating an impairment in dopamine signaling in
these cells. Remarkably, Par-4DLZ mice display sig-
nificantly increased depression-like behaviors. Col-
lectively, these results provide evidence that Par-4
constitutes a molecular link between impaired dopa-
mine signaling and depression.
Introduction
Depression, characterized mainly by low mood, amoti-
vation, anhedonia, low energy, and/or fatigue, is one of
the most prevalent disorders, with an estimated lifetime
prevalence of 16.2% in the U.S. adult population (Blazer
et al., 1994) resulting in tremendous social costs (Green-
berg et al., 1993). Although the cause of depression is
obviously multifaceted, the “monoamine hypothesis,” de-
scribing deficiency or imbalance of the monoamine sys-
tems as the cause, has been a central topic of research
(Bunney and Davis, 1965; Coppen, 1967; Schildkraut et
al., 1965). This hypothesis was generated and sup-
ported by the fact that most antidepressants share the
property of acutely modifying the serotonin or nor-
adrenaline levels at the synapse (Delay et al., 1952;*Correspondence: li-huei_tsai@hms.harvard.edu
3 These authors contributed equally to this work.Fuller, 1995; Kuhn, 1958; Leonard, 1978). However,
since clinical effects of antidepressants are usually sig-
nificantly delayed, it is now believed that an adaptation
of downstream events, including changes in gene ex-
pression and/or modification of other neurotransmitter
systems, due to chronic treatment underlies their anti-
depressant efficacy (Manji et al., 2001; Wong and Li-
cinio, 2001). Moreover, a large percentage of depres-
sive subjects are resistant to the current antidepressant
therapies (Baldessarini, 1989), demanding improve-
ment of therapeutic strategies.
Modulating the brain’s reward and motivation cir-
cuits, governed primarily by dopamine, has been one of
the attractive targets for treating depressive disorders
(Kinney, 1985). Dopamine functions in target cells through
five known subtypes of dopamine receptors (D1, D2,
D3, D4, and D5) to regulate motor control, stereotypic
behaviors, arousal, mood, motivation, and endocrine
function (Missale et al., 1998). Dopamine D2 receptor
(D2DR), the predominant D2-like dopamine receptor sub-
type, is coupled to the inhibitory G protein (Gi) to down-
regulate cAMP signaling upon activation (De Camilli et
al., 1979). Impairment in the function of D2DR is impli-
cated in various psychiatric disorders such as schizo-
phrenia, mood disorders, and drug addiction (Nestler,
2001). Understanding the details of the modulatory
events in D2DR-mediated intracellular signaling is be-
lieved to provide therapeutic targets for treating various
associated disorders.
Prostate apoptosis response 4 (Par-4) is a leucine zip-
per containing protein that was initially identified as a pro-
apoptotic factor induced by apoptotic stimuli (Sells et al.,
1994). Par-4 interacts with PKCζ (Diaz-Meco et al., 1996)
to interfere with the prosurvival activity of NFκB (Diaz-
Meco et al., 1999). Par-4 also interacts with Wilms’ tumor
1 (WT1) to inhibit the growth arrest induced by WT1
(Johnstone et al., 1996). In the nervous system, Par-4 in-
duction has been linked to neuronal death in various neu-
rodegenerative diseases (Duan et al., 1999b; Guo et al.,
1998; Pedersen et al., 2000). Although Par-4 is promi-
nently detected in synaptic compartments of the brain
(Duan et al., 1999a), a physiological role for Par-4 in
differentiated neurons has not been elucidated. In the
present study, we identify Par-4 as a modulator for
Ca2+-dependent regulation of D2DR signaling. Based
on behavioral abnormalities observed in mice with dis-
rupted Par-4/D2DR interaction, we propose that Par-4
constitutes a missing link between D2DR signaling and
the manifestation of depressive symptoms.
Results
Par-4 Directly Interacts with D2DR
To better understand the mechanisms of D2DR-medi-
ated signaling we attempted to discover modulatory
components for D2DR-mediated intracellular signaling
by exploring D2DR-interacting proteins. We identified
prostate apoptosis response 4, Par-4, as a D2DR-inter-
acting protein in a yeast two-hybrid screen using a hu-
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276man fetal embryonic brain library and the third intracel- a
clular loop of the long isoform of human D2DR (D2i3,
amino acid residues 212–373) as bait. The human Par-4 v
pcDNA clone recovered from the yeast two-hybrid
screen encompasses amino acid residues 245–342 that m
1harbor the leucine zipper domain of Par-4 (Par-4LZ, Fig-
ure 1A). The LZ domain-dependent interaction was fur- p
rther verified by the prominent interaction-dependent
growth on His−/Ura− media and by β-galactosidase ex- D
mpression (Figure 1B). The direct interaction of Par-4 with
D2i3 was demonstrated by an in vitro binding assay t
ousing purified GST-D2i3 and Par-4LZ proteins (Figure
1C). Approximately 50% of the total Par-4LZ protein
iwas pulled down by an equimolar amount of GST-D2i3
protein. Importantly, the endogenous D2DR and Par-4 w
tcan be coimmunoprecipitated from mouse brain lysate,
suggesting that the two proteins potentially form a c
tfunctional complex in vivo (Figure 1D, and Figures S1Figure 1. Interaction between Par-4 and D2DR
(A) A schematic diagram of human Par-4 protein. Par-4LZ is the protein product encoded by the cDNA clone isolated from the yeast two-
hybrid screen. Numbers represent corresponding amino acid residues. NLS, nuclear localization signal.
(B) The Par-4 and D2i3 interaction in the yeast two-hybrid assay. Upper panel: growth on the Ura−/His−/3-AT (20 mM) media. Lower panel:
β-galactosidase expression.
(C) Direct interaction between Par-4 and D2i3 in an in vitro binding assay.
(D) Coimmunoprecipitation of Par-4 and D2DR in mouse brain lysates. (Left panels) coimmunoprecipitate (CoIP) using anti-Par-4 antibody.
(Right panels) CoIP with anti-D2DR antibody. Anti-rabbit anti-GST antibody and anti-rabbit anti-hemaglutinin antibody were used as negative
controls for Par-4 IP and for D2DR IP, respectively.
(E) Relative specificity of Par-4 with D2DR interaction. The human cDNA coding the long third intracellular loops of various receptors were
cloned into pPC97 and cotransformed Mav203 yeast cells with pPC86-Par-4LZ. The expression of interaction-dependent markers, β-galacto-
sidase (upper panels), and growth on His−/Ura− media (lower panels) were examined. D2DR, dopamine D2 receptor; D3DR, dopamine D3
receptor; 5HTR, 5-hydroxytryptamine (serotonin) receptor; αAR2A, α-adrenergic receptor 2A.nd S2 in the Supplemental Data available with this arti-
le online). Interestingly, the coimmunoprecitation re-
ealed a predominant signal of w48 kDa that corres-
onds to the proposedly monomeric, unglycosylated or
ildly glycosylated D2DR species (Fishburn et al.,
995; Jarvie and Niznik, 1989). Although there is the
ossibility of selective enrichment in the sample prepa-
ation procedure and/or preferential detection of the
2DR species given that D2DR exists in differentially
odified states in vivo, this result may suggest a func-
ionally selective interaction of Par-4 with a subspecies
f D2DR in vivo, which is yet to be investigated.
To assess the relative specificity of D2DR and Par-4
nteraction, we investigated whether Par-4 interacts
ith other structurally and functionally related G pro-
ein-coupled receptors, including the dopamine D3 re-
eptor. In yeast two-hybrid assays, no significant in-
eraction-dependent marker expression was detected
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277in the Par-4LZ and receptor construct cotransformants,
indicating that Par-4 interaction with D2DR is relatively
specific (Figure 1E).
We next examined Par-4 expression in the CNS. West-
ern blot analyses revealed that Par-4 is expressed in
various brain regions, including the striatum (Figure 2A).
We examined whether Par-4 is expressed in the me-
dium spiny neurons in the striatum, in which most of
the dopaminergic inputs are processed (Murer et al.,
2002). Indeed, Par-4 is detected in the DARPP-32-posi-
tive medium spiny neurons in mouse striatal sections
(Figure 2B) (Ouimet et al., 1998). Next, we examined
whether D2DR and Par-4 coexpressed in the same cellsFigure 2. Expression of Par-4 and D2DR
(A) Par-4 expression in various brain regions.
Lysates were prepared from indicated mouse
brain regions and analyzed by Par-4 Western
blot (200 g protein/lane).
(B) Par-4 expression in DARPP-32-positive
neurons in the striatum. Par-4 (DAB/Ni; dark
brown) and DARPP-32 (DAB; purple). A
higher magnification is shown in the inset.
Scale bars, 10 m in the whole section and
1 m in the inset.
(C) Colocalization of D2DR and Par-4 in the
striatum. A double fluorescence immuno-
staining of D2DR and Par-4 on the coronal
section of a wild-type mouse brain. Green,
red, and blue colors indicate Par-4, D2DR,
and nucleus (DAPI), respectively. Higher
magnifications of a representative cell with
significant colocalization are shown in the in-
sets. Scale bars, 10 m.
(D) Colocalization of Par-4, D2DR, and syn-
aptophysin in cultured mouse striatal neu-
rons (DIV11). Magnified views of processes
(panels e–h and m–p) and cell periphery
(panels i–l) are also shown. Scale bars repre-
sent 2.5 m in panels (a)–(d) and 1 m in
panels (e)–(l).
(E) Cofractionation of D2DR and Par-4 in the
synaptosomal fraction. The schematic frac-
tionation procedure is shown on the left, and
a Western blot analysis of equivalent volume
of the fractions is on the right. Fractionation
was performed in duplicate. The bracket
indicates the additional higher-molecular-
weight D2DR immunoreactivity.in the striatum. 90.3% ± 2.6% and 82.7% ± 1.7% of
striatal neurons expressed detectable levels of D2DR
and Par-4, respectively. The level of Par-4 expression
appears variable in different cell types (Figure 2C, Fig-
ure S3, and data not shown). The Par-4 positive cells
were mostly D2DR-positive (w97%), demonstrating
that Par-4 indeed is expressed in D2DR-positive neu-
rons in the striatum. Furthermore, D2DR, Par-4, and syn-
aptophysin colocalize in cultured striatal neurons (Fig-
ure 2D). The colocalization is detected primarily in the
periphery of the cell soma (Figures 2Da–2Dd and 2Di–
2Dl and Figure S4A) and neuronal processes (Figures
2Da–2Dh and 2Dm–2Dp, and Figures S4A and S4B),
Cell
278where the main pool of functional D2DR is localized T
l(Hersch et al., 1995). Consistently, Par-4 and D2DR co-
fractionated in the synaptosomal fraction (Figure 2E). r
cTaken together, these results strongly suggest a physio-
logical role for Par-4 in D2DR-mediated dopamine sig-
naling in the striatum, which is likely conferred by its D
direct interaction with D2i3. a
o
iCalmodulin Competes with Par-4 in Binding to D2i3
in a Ca2+-Dependent Manner T
tThe binding domain of D2DR to Par-4 was localized to
the first 30 amino acid residues of D2i3 as indicated by p
tin vitro binding assays (Figures 3A–3C). Intriguingly, the
binding region (amino acid residues 212–241) harbors o
(the site known to interact with calmodulin (Bofill-Car-
dona et al., 2000). Indeed, calmodulin binds to D2i3 in a o
rCa2+-dependent manner (Figure 3D), whereas Par-4LZ
binding is constitutive regardless of the presence of P
tCa2+ (Figure 3E). To determine whether Par-4 and cal-
modulin compete for binding to D2i3, we examined the
tassociation of Par-4LZ protein with D2i3 in the pres-
ence of increasing levels of calmodulin. An increased l
cbinding of calmodulin in the presence of Ca2+ interfered
with the interaction of Par-4LZ with D2i3 (Figure 3F), a
eindicating that calmodulin can displace Par-4 from D2i3
in a Ca2+-dependent manner. Consistent with the in vi- a
Rtro binding experiments, the coimmunoprecipitation of
Par-4 with D2DR-EGFP was significantly reduced in the a
wpresence of either ionomycin, a Ca2+ ionophore, or
thapsigargin, an intracellular Ca2+ mobilizer (Lytton et i
1al., 1991) in the stable D2DR-EGFP cell line, indicating
that the Par-4/D2DR association can be downregulated i
oby increased Ca2+ in the cellular context (Figure 3G).
t
rPar-4 Loss of Function Downregulates D2DR
1Efficacy to Reduce Inhibitory Tone
mon Dopamine-Mediated cAMP Signaling
It has been reported previously that calmodulin binding
dto D2i3 negatively regulates D2DR by interfering with
pthe coupling of the Gi-protein in a noncompetitive man-
Sner (Bofill-Cardona et al., 2000). Thus, an equilibrium
wshift from the Par-4/D2DR interaction to the calmo-
Pdulin/D2DR interaction by augmented Ca2+ concentra-
ttions most likely results in a downregulation of D2DR
defficacy, thereby relieving the inhibitory tone on dopa-
Wmine-mediated downstream signaling. To assess the
nimpact of Par-4 loss of function on D2DR efficacy, we
rsought to silence Par-4 expression, using RNA interfer-
ience (RNAi) against Par-4 in a DNA-based vector (Sui
net al., 2002). The Par-4 siRNA effectively knocked down
Dthe expression of endogenous Par-4 protein in the
oHEK293 cells (Figure 4A) and in cultured rat striatal neu-
brons (Figure 4B). We next analyzed the direct effect of
oPar-4 loss-of-function on D2DR efficacy by measuring
iD2DR-mediated inhibition of forskolin-activated ade-
nnylyl cyclase activity (Sokoloff et al., 1992) in a stable
cD2DR-EGFP cell line. While D2DR activation by quinpir-
cole, a D2-like dopamine receptor agonist, resulted in a
tsignificant decrease in forskolin-activated cAMP accu-
mulation in mock-transfected cells, the downregulation
of adenylate cyclase was not detectable in Par-4 siRNA- D
itransfected cells (Figure 4C). Moreover, Par-4 siRNA
produced an enhanced dopamine-mediated cAMP ac- c
cumulation in cultured rat striatal neurons (Figure 4D).aken together, these observations indicate that Par-4
oss-of-function negatively affects D2DR efficacy, thereby
elieving the inhibitory tone on dopamine-mediated
AMP signaling.
isruption of the Interaction between Par-4
nd D2DR Results in Upregulation
f Dopamine-Mediated cAMP Signaling
n Par-4DLZ Striatal Neurons
o further test the physiological relevance of the in-
eraction between Par-4 and D2DR in vivo, we em-
loyed a deletion mutant mouse, Par-4DLZ, that lacks
he expression of the C-terminal leucine zipper region
f Par-4 that is responsible for interaction with D2DR
Figures 1A, 1B, and 5A) (unpublished data). The knock-
ut of exons 4 and 5 in the Par-4 locus by homologous
ecombination resulted in expression of the truncated
ar-4LZ protein instead of full-length Par-4 in the mu-
ant brain extract (Figure 5B).
To examine the importance of the Par-4/D2DR in-
eraction in dopamine-cAMP signaling in vivo, we ana-
yzed the dopamine-mediated cAMP accumulation in
ultured primary striatal neurons derived from wild-type
nd Par-4DLZ embryos. No overt morphological differ-
nces between cultured striatal neurons from wild-type
nd Par-4DLZ embryos were observed (data not shown).
emarkably, mutant neurons exhibited a significantly
ltered response profile of cAMP levels upon treatment
ith increasing concentrations of dopamine in compar-
son with wild-type neurons (Figure 5C). Specifically,
–10 M of dopamine markedly elevated cAMP levels
n mutant neurons, indicating a reduced inhibitory tone
n dopamine-mediated cAMP signaling. The fact that
his dopamine concentration is within the physiological
ange of phasic dopamine in the striatum (Jones et al.,
998), as well as the affinity (Kd) of dopamine to mam-
alian D2DR (Bunzow et al., 1988), is noteworthy.
To further delineate the altered cAMP response to
opamine treatment in Par-4DLZ neurons, we em-
loyed D1 and D2 antagonists in the assay. When the
CH23390, a D1DR-specific antagonist, was cotreated
ith dopamine, the enhancement of cAMP response in
ar-4DLZ neurons was abolished (Figure 5D), indicating
hat activation of dopamine D1 receptors (D1DR) un-
erlies the cAMP response at 1–10 M of dopamine.
hen dopamine and sulpiride, a D2-specific antago-
ist, were cotreated in the wild-type neurons, the cAMP
esponse was enhanced at 1–10 M dopamine, which
s reminiscent of the increase observed in Par-4DLZ
eurons (Figure 5E, left panel). This result indicates that
2DR activity plays a role in forming an inhibitory tone
n the cAMP system in this concentration range. Nota-
ly, the D2-specific antagonist revealed no such effect
n Par-4DLZ neurons (Figure 5E, right panel), support-
ng the idea that D2DR function is impaired in these
eurons. Based on these results, it is likely that the de-
reased inhibitory tone caused by impaired D2DR effi-
acy in Par-4DLZ neurons contributes to the concen-
ration-specific upregualtion of the cAMP response.
opamine-Dependent CREB Activity Is Upregulated
n the Striatal Neurons from Par-4DLZ Mice
AMP-responsive element binding protein (CREB) is adownstream transcription factor whose activity is regu-
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279Figure 3. Binding of Par-4 and Calmodulin to a Common Region in the D2i3
(A) Mapping of the Par-4 binding region in D2i3. A series of GST fusion proteins containing D2i3 portions, as indicated, were generated,
purified, and used for in vitro binding assays with purified Par-4LZ protein shown in (B).
(B) In vitro binding assays of GST fusion protein shown in (A) with Par-4LZ protein.
(C) Overlap between the Par-4 and calmodulin binding motif in D2i3. The primary sequence of the human D2i3 is shown. Underlined is the
region binding to Par-4LZ protein. Bold letters indicate the calmodulin binding motif.
(D) Ca2+-dependent binding of calmodulin to D2i3. CaM, calmodulin.
(E) Constitutive binding of Par-4LZ protein to D2i3.
(F) Competitive binding of Par-4LZ protein and calmodulin. Purified Par-4LZ protein and increasing concentrations of bovine calmodulin were
incubated with GST-D2i3212–241 protein (50 nmol) in the presence of Ca2+ (200 M) in molar ratios, as indicated, and analyzed by Western
blotting. Immunoreactivities for calmodulin (open bars) and Par-4LZ proteins (closed bars) in the GST pulldowns were quantified from scanned
images using ImageMaster 2D Elite Software (Amersham Pharmacia). Error bars indicate ±SEM. ** indicates statistical significance as deter-
mined by the Student’s two-tailed t test; p % 0.01 (n = 3).
(G) Ca2+-dependent reduction of Par-4/D2DR interaction in HEK293 cells. The stable D2DR-EGFP-expressing HEK293 cell line was treated
with ionomycin (2 M) or thapsigargin (1.5 M) for 1 hr at room temperature, and the anti-GFP antibody immunoprecipitates were analyzed
by Western blotting. Brackets, D2DR-EGFP; closed arrows, Par-4; asterisks, IgG. Immunoreactivities for D2DR-EGFP and endogenous Par-4
were quantified from scanned images using ImageMaster 2D Elite Software (Amersham Pharmacia). Two-tailed t tests: **, p % 0.01; *, p %
0.05. n = 4 for ionomycin treatment and n = 2 for thapsigargin treatment.
Cell
280Figure 4. Reduced D2DR Efficacy by Par-4
Loss of Function
(A) Knockdown of the endogenous Par-4
protein by siRNA in HEK293 cells. Lysates
from mock (mock)- and Par-4 RNAi-trans-
fected cells (siRNA) were analyzed by West-
ern blotting 48 hr after transfection. Mock,
an siRNA construct ineffective on Par-4 ex-
pression.
(B) Knockdown of the Par-4 protein by siRNA
in the rat striatal neurons. The lysates from
rat striatal neurons 3 days after siRNA
nucleofection were analyzed by Western
blotting.
(C) Forskolin-stimulated cAMP accumulation
with increasing concentrations of quinpirole
was measured by cAMP enzyme immuno-
assay in the mock-transfected (open bars)
and Par-4 siRNA-transfected cells (closed
bars). Statistical significance at each con-
centration as determined by the Student’s
two-tailed t test is indicated by asterisks. *,
p % .05; **, p % 0.01, (n = 3). The overall
difference between mock- and Par-4 RNAi-
treated samples was statistically significant
(p% 0.0005, two-way ANOVA). Error bars in-
dicate ±SEM. V, vehicle.
(D) The rat striatal neurons were mock-nucleofected (open bars) or nucleofected by Par-4 siRNA (closed bars) before plating and DIV9 neurons
treated with vehicle (V) or dopamine for 30 min at room temperature were subjected to the cAMP enzyme immunoassay. Statistical signifi-
cance was determined by the Student’s two-tailed t test; *, p % 0.05 (n = 2). Error bars indicate ±SEM.lated by the cAMP-PKA signaling pathway. To examine s
bwhether the altered dopamine-mediated cAMP signal-
ing in Par-4DLZ neurons has further impact on down- c
sstream events, we analyzed the phosphorylation status
of CREB at serine 133 (S133), a site that is phosphory- a
plated by the cAMP-dependent protein kinase (PKA) in
response to dopamine (Figure 5F) (Gonzalez et al., m
i1989). In wild-type neurons, CREB S133 phosphoryla-
tion was significantly decreased upon dopamine treat- s
cment in a dose-dependent manner. Interestingly, the
dopamine-induced downregulation of CREB S133 phos- M
phorylation was not observed in Par-4DLZ neurons. l
When compared to that in wild-type neurons, CREB 4
S133 phosphorylation is markedly upregulated in Par- p
4DLZ neurons, which is consistent with the observed t
upregulation of dopamine-mediated cAMP accumula- m
tion in Par4-DLZ neurons. This result suggests that the v
downstream events of dopamine-mediated cAMP sig- t
naling are affected in the absence of Par-4/D2DR in- c
teraction. m
i
tPar-4DLZ Mice Show Increased
oDepression-like Behaviors
aDysfunction of the mesolimbic dopamine system is one
tof the leading candidates for the etiology of certain
ssymptoms characteristic of depression, such as anhe-
Idonia and amotivation (American Psychiatric Associa-
ition, 2000). As such, we tested whether abnormalities
tin dopamine-mediated signaling in Par-4DLZ mice have
aphysiological consequences related to depression-like
Pbehaviors by employing the Porsolt’s forced swim test
(FST), a well-established behavioral paradigm to detect
bdepression-like behavior in rodents (Porsolt et al.,
t1977). Enhanced immobility with no attempt to escape
in this test reflects a “depressive mood,” as antidepres- tants were shown to influence this behavior. Remarka-
ly, Par-4DLZ mice display elevated immobility scores
ompared to wild-type, hence an increased depres-
ion-like behavior (Figure 6A; Supplemental Movies S1
nd S2). To verify this result, we performed the tail sus-
ension test (TST), in which a rapid adoption of an im-
obile posture is shown to reflect a “depressive mood”
n rodents (Steru et al., 1985). Par-4DLZ mice showed
ignificantly elevated immobility scores on the TST
ompared with those of wild-type mice (Figure 6B;
ovies S3 and S4), confirming increased depression-
ike behaviors in Par-4DLZ mice. We next tested Par-
DLZ mice in the novelty-suppressed feeding (NSF)
aradigm, which has been used effectively to assess
he efficacy of antidepressants by eliciting competing
otivations such as the drive to eat and the fear of
enturing into the open field (Santarelli et al., 2003). In
his test, Par-4DLZ mice exhibited a significantly in-
reased latency to contact food, indicative of reduced
otivation in an aversive environment, a feature of clin-
cal depression (Figure 6C, Movies S5 and S6). In addi-
ion, we analyzed behaviors of Par-4DLZ mice in the
pen field to determine whether the mutant mouse has
bnormalities in exploratory activity, since reduced ac-
ivity in the open field has been correlated with depres-
ion-like behaviors in rodents (El Yacoubi et al., 2003).
ndeed, the total exploratory activity of Par-4DLZ mice
n an open field, measured by total distance traveled in
he arena, was decreased (Figure 6D and Movies S7
nd S8), supporting the depression-like behaviors in
ar-4DLZ mice.
To examine whether the enhanced depression-like
ehaviors in Par-4DLZ mice are compromised by a po-
ential anxiety-like behavior, we analyzed the ambula-
ory pattern of the mice in the open field test, in which
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281Figure 5. Altered Dopamine-Mediated cAMP Signaling in Par-4DLZ Mice
(A) A schematic diagram of mouse Par-4 and Par-4LZ proteins.
(B) Expression of truncated Par-4 protein in the Par-4DLZ mouse. Par-4 protein expression levels in total brain lysates from wild-type and
mutant mice were analyzed with Western blotting. Open arrowhead, Par-4; closed arrowhead, Par-4LZ proteins; asterisks, a nonspecific
band recognized by anti-Par-4 antibody in both wild-type and Par-4DLZ brain lysates.
(C) Altered dopamine-stimulated cAMP response profile in Par-4DLZ neurons. Cultured DIV11 striatal neurons from wild-type (open bars) and
Par-4DLZ mice (closed bars) were treated with increasing concentrations of dopamine, as indicated, and cAMP levels from the cell lysates
were measured using cAMP enzyme-immunoassays (n = 4).
(D) Abolished dopamine-mediated cAMP response upon D1-like dopamine receptor antagonist treatment in striatal neurons. Cultured DIV12
striatal neurons from wild-type (open bars) and Par-4DLZ mice (closed bars) were cotreated with SCH23390 (1 M) and increasing concentra-
tions of dopamine as indicated, and cAMP levels from the cell lysates were measured (n = 2).
(E) Differential dopamine-stimulated cAMP responses upon D2-like dopamine receptor antagonist treatment. Cultured DIV12 striatal neurons
from wild-type (left panel) and Par-4DLZ embryos (right panel) were treated with increasing concentrations of dopamine in the absence (open
bars) or presence of sulpiride (1 M; closed bars) as indicated, and cAMP levels from the cell lysates were measured (n = 3).
(F) Enhanced dopamine-induced phosphorylation of CREB at serine 133 in Par-4DLZ neurons. ELISAs for S133 phospho-CREB (pCREB) and
total CREB were carried out in the cultured striatal neurons from wild-type (open bars) and Par-4DLZ mice (closed bars) The DIV11 neurons
were treated with increasing concentrations of dopamine as indicated. The ratios of pCREB/CREB were subjected to analyses (n = 3).
Error bars indicate ±SEM. *p % 0.05, ** p % 0.01; one-way ANOVA. V, vehicle.the level of center activity has been known to inversely
reflect anxiety level (El Yacoubi et al., 2003). The ambu-
latory pattern and center activities of wild-type andPar-4DLZ mice were not significantly different, suggest-
ing that anxiety level is not altered in Par-4DLZ mice
(Figure 6E). To further verify this interpretation, we per-
Cell
282Figure 6. Depression-like Behaviors of Par-4DLZ Mice
(A) Porsolt’s forced swim test (FST). Cumulative immobile period (passive floating without hindleg movements) was measured for a 6 min test
session (n = 7/genotype).
(B) Tail suspension test (TST). Cumulative immobile period (no movement of four limbs) was measured for a 6 min test session. (n =
7/genotype).
(C) Novelty-suppressed feeding (NSF). Latency to contact food was analyzed (n = 10 for wild-type and n = 12 for Par-4DLZ mice).
(D) Exploratory activity in the open field test. Total distance of the mouse traveled in the arena was measured for a 5 min test session (n = 8
for wild-type and n = 9 for Par-4DLZ mice).
(E) Ambulatory pattern analyses in the open field. Traces of the movements of individual mice in the arena were superimposed (left panel,
n = 8/genotype). The arena was subdivided into 16 (4 × 4) rectangular areas, and the time spent in the four center subdivisions was quantified
(n = 8 for wild-type and n = 9 for Par-4DLZ mice).
(F) Elevated plus maze test. Movements of the mice were monitored in the maze and time spent in each area was quantified in a 5 min test
session. The fraction of time spent in each area over the total test period was analyzed (n = 8 for wild-type and n = 13 for Par−4DLZ mice).
(G) Normal motor coordination of Par-4DLZ mice. Latency to the first fall was analyzed (n = 7/genotype).
Mean values (bars) and individual data points (circles) are plotted. Error bars indicate ±SEM; *p % 0.05, ** p % 0.01; one-way ANOVA. NS,
not significant; +/+, wild-type mice (open bars); D/D, deletion mutants (shaded bars).formed the elevated plus maze test, a test of anxiety- a
olike behavior (Lister, 1987). In this test, the fraction of
time spent in the open and closed arms of the maze m
mwas not significantly different between Par-4DLZ and
wild-type mice (Figure 6F; Movie S9), further supporting nnormal anxiety level in Par-4DLZ mice. In addition, no
vert anatomical abnormalities of the adult Par-4DLZ
ouse brain were detected (Figure S6), and the perfor-
ance of Par-4DLZ mice in a rotarod test was not sig-
ificantly different from that of wild-type mice (Figure
Par-4 Links Dopamine Signaling and Depression
2836G and Movie S10), indicating that the enhanced de-
pression-like behavior of Par-4DLZ mice is not likely
due to defects in brain development and/or motor coor-
dination. Collectively, these results show that a dis-
rupted modulation of dopamine signaling caused by
loss of Par-4/D2DR interaction in Par-4DLZ mice is as-
sociated with depression-like behaviors.
Discussion
In the present study, we have reported a function of
Par-4 as a modulatory component in dopamine signal-
ing, demonstrating that Par-4/D2DR complex formation
is necessary to maintain an inhibitory tone on dopa-
mine-mediated cAMP signaling generated by D2DR in
the low Ca2+ condition (Figure 7A). A shift in equilibrium
toward the calmodulin/D2DR complex can occur when
Ca2+ influx activates calmodulin, thereby relieving the
D2DR-mediated inhibitory tone on cAMP signaling (Fig-
ure 7B). Disruption of Par-4/D2DR interaction in Par-
4DLZ mice may facilitate calmodulin/D2DR complex
formation upon Ca2+ influx, hence an upregulation of
dopamine-cAMP-CREB signaling, which may contrib-
ute to the increased intensity of depression-like beha-
viors in the multiple behavioral paradigms tested (Fig-
ure 7C). Thus, identification of Par-4/D2DR interaction
potentially reveals a mechanism for crosstalk between
Ca2+ signaling and dopamine-mediated cAMP sig-
naling.
The physiological relevance of the interaction be-
tween Par-4 and D2DR and its modulation of cAMP sig-
naling is signified by depression-like behaviors in Par-
4DLZ mice. This observation is of particular interest
due to ample evidence suggesting that impairment of
dopamine signaling is involved in the manifestation of
depression (Manji et al., 2001; Willner, 1995). For exam-
ple, anhedonia and amotivation, symptoms prominent
in depressive patients, are mainly governed by dopa-
mine neurotransmission in reward and motivation cir-
cuits (Nader et al., 1997). Moreover, levels of dopamine
metabolites in cerebrospinal fluid are reduced in de-
pressive subjects (Bowden et al., 1997). Conversely, a
depressive syndrome is frequently encountered in sub-
jects affected by Parkinson’s disease, a nigrostriatal hy-
podopaminergic disorder (Burn, 2002). Notably, D2DR an-
tagonists can induce “pharmacogenic depression” in
schizophrenic patients (Willner, 1995), and chronic
treatment with antidepressants produces behavioral
sensitization to D2DR agonists (Maj et al., 1996). These
observations unequivocally suggest that perturbed
D2DR-mediated signaling may underlie the manifesta-
tion of depressive symptoms and that effects of antide-
pressants also involve an adaptation of D2DR signaling
pathways. Nonetheless, the underlying molecular mecha-
nisms have not been elucidated. In the present study,
we have reported perturbed dopamine signaling in Par-
4DLZ mice that is caused by disrupted Par-4/D2DR in-
teraction. Since Par-4DLZ mice exhibit depression-like
behaviors, it is likely that the perturbed dopamine sig-
naling in Par-4DLZ mice may mimic certain aspects of
pathological states of depression at molecular levels,
such as an altered CREB activity.
Indeed, roles for cAMP-CREB signaling in the patho-Figure 7. A Model for the Involvement of Par-4 in the Ca2+-Depen-
dent Regulation of D2DR Signaling
Complex formation between Par-4 and D2DR is necessary to main-
tain the inhibitory tone on cAMP signaling generated by D2DR.
(A) The Ca2 influx activates calmodulin, shifting the equilibrium to-
ward a calmodulin/D2DR complex. As a result, D2DR efficacy is
reduced, thereby relieving D2DR-mediated inhibitory tone on cAMP
signaling. (B) Disruption of Par-4/D2DR interaction in Par-4DLZ
mice facilitates calmodulin/D2DR complex formation upon Ca2+ in-
flux, hence an upregulation of dopamine-cAMP signaling including
the activation of downstream CREB (C). CaM, calmodulin; AC, ade-
nylyl cyclase; PKA, cAMP-dependent protein kinase.physiology of depression and in the action of antide-
pressants have been suggested by numerous studies.
However, the impact of the changes in cAMP-CREB
signaling on the manifestation of depression and the
outcome of chronic antidepressant treatment is com-
plex. In some studies, the upregulation of cAMP-CREB
is causally correlated with chronic antidepressant ef-
fects (Chen et al., 2001; Dowlatshahi et al., 1998). On
the other hand, there is also evidence that blockade
of cAMP-CREB signaling underlies antidepressant-like
effects. For example, repeated antidepressant admin-
istration decreases levels of CREB phosphorylation in
the frontal cortex (Manier et al., 2002). Furthermore, in-
hibition of CREB activity in the nucleus accumbens
produces an antidepressant-like effect in animal mod-
els of depression, whereas overexpression of CREB in
Cell
284Dthis region elicits opposite effects (Newton et al., 2002;
4Pliakas et al., 2001). Collectively, it appears that the ef-
4fect of CREB activity on depression-like behaviors is
S
brain region-specific, mediating differential responses t
to antidepressants in the nucleus accumbens and other l
brain regions. In the present study, we have demon-
strated an upregulation of dopamine-dependent cAMP- A
ACREB signaling in the striatal neurons from Par-4DLZ
emice in association with depression-like behaviors.
aThis observation is in agreement with reports that an
a
increase in CREB activity in the D2DR-rich nucleus ac- p
cumbens, a major target of mesolimbic dopaminergic C
Ctracts in the striatum, is connected to behavioral re-
msponses to emotional stimuli and depressive symptoms
b(Barrot et al., 2002; Nestler et al., 2002). Thus, the en-
Mhanced dopamine-dependent CREB activity and asso-
f
ciated changes in the gene expression profile in the re- C
ward circuits are likely to contribute to depression-like
behaviors in Par-4DLZ mice. I
MIt is well established that D2DR function is required
sfor normal motor coordination (Viggiano et al., 2003).
NInterestingly, Par-4DLZ mice do not exhibit overt de-
mfects in motor skills (Figure 6G and Movies S1–S10).
p
We speculate that, by disrupting the direct interaction 1
between D2DR and Par-4, only Par-4-mediated modu- p
olatory events in D2DR signaling are impaired in vivo,
bwhich may be functionally important only in certain cir-
mcumstances, such as those related to controlling mood.
aThe data presented here do not rule out the possi-
g
bility that the behavioral phenotypes of Par-4DLZ mice h
are due to direct modifications, by a similar mecha- u
1nism, of other neurotransmitter systems such as sero-
ptonin or norepinephrine. However, such a possibility is
bless likely for the following reasons. First, calmodulin-
wmediated downregulation of D2DR efficacy is relatively
l
specific (Bofill-Cardona et al., 2000). Second, our study D
of the interaction of Par-4 with the long third intracellu- g
tlar loops of the related G protein-coupled receptors
etested did not reveal any significant interaction, indicat-
bing that Par-4 does not interact with GPCRs in a pro-
lmiscuous manner. Third, a comparable upregulation of
l
cAMP signaling upon treatment of serotonin and nor- 5
epinephrine in Par-4DLZ striatal neurons was not de- m
ptected (Figure S7). Nevertheless, given the broad ex-
tpression of Par-4 in the CNS, additional neuronal
3functions of Par-4 and the potential contribution of




wIn Vitro Binding Assay
mpPC97-D2i3 and pPC86-Par-4LZ plasmids were digested with SalI
rand NotI and cloned into pGEX4T-2 (Amersham-Pharmacia) using
tthe same restriction sites to make GST-D2i3 and GST-Par-4LZ fu-
4sion proteins, respectively. GST fusion proteins were expressed in
tBL21 bacteria and purified following the manufacturer’s instruc-
Itions. For the in vitro binding assay, 500 nmol of GST-Par-4LZ fu-
asion protein in PBS was digested with 0.2 NIH units thrombin
((Sigma) for 2 hr at room temperature, the reaction was stopped by
adding 10 M PMSF (Sigma), and the mixture was incubated for
an additional 1 hr at 4°C. The GST portion of the digested protein I
Dwas removed by glutathione Sepharose (Amersham-Pharmacia).
The supernatant was equilibrated to final 1× binding buffer (200 i
bmM NaCl, 0.2% Triton X-100, 0.2 mg/ml BSA, and 50 mM Tris [pH,
7.5]). Binding reaction was initiated by adding 500 nmol of GST- t2i3 (50 nM of GST-D2i3221–241 in the competition assay) to Par-
LZ protein in the 1× binding buffer and incubated for 2–3 hr at
°C. GST-D2i3 was precipitated using 100 l of 10% glutathione
epharose in 1× binding buffer. The precipitate was washed three
imes with 1× binding buffer and resuspended in 2× SDS sample
oading buffer.
ntibodies
nti-Par-4 anti-rabbit polyclonal (R334) (Cheema et al., 2003; Duan
t al., 1999a), anti-Par-4 anti-mouse monoclonal (A10) (Bieberich et
l., 2003), anti-D2DR anti-goat polyclonal (N19) (Scott et al., 2002),
nti-rabbit polyclonal (H50) (Dunah et al., 2002), anti-GST rabbit
olyclonal, and monoclonal antibodies were purchased from Santa
ruz Biotechnology. Anti-rabbit anti-DARPP-32 antibody was from
ell Signaling. Anti-synaptophysin (SVP-38) and anti-α-tubulin
onoclonal antibodies were from Sigma. Anti-rabbit anti-GFP anti-
ody and Cy5-conjugated anti-mouse IgG were purchased from
olecular Probes. FITC-conjugated anti-rabbit IgG was purchased
rom ICN, and Texas red-conjugated anti-goat IgG, from Santa
ruz Biotechnology.
mmunoprecipitation
ice were euthanized in a CO2 chamber, and the brains were dis-
ected out and Dounce homogenized in the BF2 buffer (150 mM
aCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and 50
M Tris [pH, 8.0], 5 mM EDTA, 5 mM EGTA, 5 mM glycerol-2-phos-
hate, 2 mM sodium pyrophosphate, 5 mM NaF, 2 mM Na3VO4,
mM DTT, phosphatase inhibitor cocktail 1 (Sigma), EDTA-free
rotease inhibitor cocktail (Roche), and 10 M ALLM [Calbi-
chem]). For coimmunoprecipitation using anti Par-4 antibody, the
rain was first homogenized in BF1 (150 mM NaCl, 1% NP-40, 50
M Tris [pH, 8.0], EDTA-free protease inhibitor cocktail (Roche),
nd 10 M ALLM [Calbiochem]), centrifuged for 15 min at 12,000×
, and the pellet was resuspended in BF2 and homogenized. The
omogenate was centrifuged (10,000× g) and the supernatant was
sed for immunoprecipitation. Protein extract was incubated with
g of antibody on a rocking plate for 1 hr at 4°C. 100 l 10%
rotein-G Sepharose (Amersham-Pharmacia) in the same lysis
uffer was added and incubated for an additional 45 min at 4°C
ith gentle shaking. The precipitate was washed three times with
ysis buffer and resuspended in 2× SDS sample loading buffer. For
2DR co-immunoprecipitation, anti-D2DR antibodies were conju-
ated to Dynabeads (DYNAL) following the manufacturer’s instruc-
ion and incubated with brain lysates. The proteins were eluted in
thanolamine, lyophilized, and dissolved in 2× SDS sample loading
uffer. For coimmunoprecipitation from the stable D2DR-EGFP cell
ine, cells cultured to w90% confluency in the 10 cm plate were
ysed in a lysis buffer (150 mM NaCl, 1% Triton X-100, 5 mM EDTA,
mM EGTA, 50 mM Tris [pH, 8.0], 5 mM glycerol-2-phosphate, 2
M sodium pyrophosphate, 5 mM NaF, 2 mM Na3VO4, 1 mM DTT,
hosphatase inhibitor cocktail-I (Sigma), EDTA-free protease inhibi-
or cocktail (Amersham-Pharmacia), 10 M ALLM [Calbiochem]) for
0 min with gentle shaking at 4°C. Lysates were Dounce homoge-
ized and centrifuged at 12,000 × g for 15 min. Supernatants were
sed for immunoprecipitation.
mmunohistochemistry
ice were anesthetized with avertin and perfused transcardially
ith PBS, followed by 4% paraformaldehyde/PBS. Comparable 6
m thick paraffin coronal brain sections were deparaffinized and
ehydrated. Antigen retrieval was performed by microwave irradia-
ion. Sections were incubated with primary antibodies overnight at
°C. Bound antibodies were detected by standard streptavidin-bio-
in-peroxidase methods (Vector Laboratories, Burlingame, CA).
mmunostaining was performed using ant-rabbit anti-D2DR (1:50),
nti-mouse anti-Par-4 (1:100), and anti-rabbit anti-DARPP-32
1:100) antibodies.
mmunocytochemistry
IV11–14 mouse striatal neurons cultured on coverslips were fixed
n cold 4% paraformaldehyde/PBS for 1 hr. Coverslips were incu-
ated for 2 hr in the blocking solution (2% goat serum and 1%
riton X-100 in PBS), and primary antibodies were incubated for
Par-4 Links Dopamine Signaling and Depression
2856–12 hr and secondary antibodies, for 2 hr at room temperature in
the blocking solution. Anti-rabbit anti-Par-4 polyclonal antibody
was used at a dilution of 1:200, anti-D2DR anti-goat polyclonal anti-
body, at 1:200, and anti-synaptophysin anti-mouse monoclonal an-
tibody, at 1:300.
cAMP Enzyme-Immunoassay
DIV 11–14 neurons cultured in 24-well plates were replaced with
neurobasal media supplemented with 10 mM HEPES (pH, 7.4) con-
taining drugs indicated for 50 min at room temperature; cells were
lysed in 200 l of 0.1 M HCl solution for 15 min with gentle shaking
and spun in the microcentrifuge tubes. cAMP concentration of the
supernatant was measured using the cAMP-Enzyme Immunoassay
Kit (Assay Designs) following the manufacturer’s instructions. Con-
centrations of cAMP were normalized using protein concentrations
measured by Biorad Protein Assay System (Bio-Rad).
Forskolin-Activated Adenylate Cyclase Activity Assay
D2DR-mediated inhibition of forskolin-stimulated cAMP production
was analyzed in a stable HEK293 cell line expressing D2DR-EGFP.
Cells cultured in 24-well dishes were preincubated with rolipram
(10 M) for 15 min and subsequently treated with forskolin (1 M)
and increasing concentrations of quinpirole, as indicated, for 20
min at room temperature. cAMP concentration of the cell lysates
was measured by cAMP-EIA.
Behavioral Tests
Porsolt’s forced swim test was performed as previously described
(Porsolt et al., 1977). Mice were placed in a Plexiglass chamber
(diameter, 18 cm; height, 30 cm) filled with water (8 cm deep, 25°C),
and immobility (passive floating without hindleg movements) was
scored during the 6 min test session. A tail suspension test was
carried out as previously described (Steru et al., 1985). A mouse
was suspended by the tail to a rod in a shielded chamber. Two
blind observers measured the immobility (no foreleg and hindleg
movement) during the 6 min test session, and the mean values
were used for analysis. Novelty-suppressed feeding behavior was
carried out as previously described (Santarelli et al., 2003). Mice
were deprived of food for 48 hr and then exposed to the food in a
novel context, a white-lit arena (50 × 35cm2) and monitored using
the TSE Videomot 2 video tracking system (TSE Systems). The lat-
ency to contact food was analyzed. In the open field test, the ex-
ploratory behaviors of the mice were monitored in the 50 × 35cm2
white-lit arena for 5 min using the TSE Videomot 2. To analyze cen-
ter activity, the arena was divided into 16 rectangular areas (4 ×
4) and time spent in the central four subdivisions was quantified.
Elevated plus maze tests were carried out as previously described
(Lister, 1987) using the H10-35-EPM system (Coulbourn Instru-
ments). Mice were placed in the center area of the plus maze, and
their movements were monitored using TSE Videomot 2. Time
spent in the open arms, in the closed arms, and in the center area
was quantified. Rotarod tests were performed as previously de-
scribed (Ona et al., 1999) using the Economex Rotarod System (Co-
lumbus Inc.). Prior to testing, mice were trained in three sessions
(15 min each) on the same rotarod over a period of 2 days. Latency
to fall was measured at 4 – 40 rpm with 1%/s increments in speed.
Supplemental Data
Supplemental Data include Supplemental Experimental Pro-
cedures, seven figures, and ten movies and can be found with this
article online at http://www.cell.com/cgi/content/full/122/2/275/
DC1/.
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